Title: | Clinical practice guidelines on the diagnosis and treatment of hepatitis C infection in patients with chronic kidney disease |
Edition: | Original |
Classification: | Rapid advice guideline |
Field: | Diagnosis and Treatment |
Countries and regions: | China |
Guidelines users: | 临床医生,肾脏病科医护 |
Evidence classification method: | GRADE |
Development unit: | Expert group on the diagnosis and treatment of hepatitis C infection in patients with chronic kidney disease |
Registration time: | 2022-11-27 |
Registration number: | PREPARE-2022CN780 |
Purpose of the guideline: | 丙型肝炎病毒(hepatitis C virus, HCV)感染在慢性肾脏病(chronic kidney disease, CKD)患者中高发,患者在抗HCV治疗方面具有特殊性。随着直接抗病毒药物(direct acting antiviral agent, DAA)问世并广泛应用于临床,CKD患者合并HCV感染的预后获得了极大的改善。近年来HCV治疗领域进展迅速,多种DAA相继在国内获批上市。为此,我国肾脏病、感染病和肝病专家组在2019年发表的《CKD合并HCV感染诊断和治疗的专家共识临床实践指南》基础上,以国内外临床研究进展为依据,结合现阶段我国实际情况,更新形成了本共识临床实践指南,以期为CKD合并HCV感染患者的规范化诊治提供指导性建议。 |